Homotypic antibodies target novel E glycoprotein domains after natural DENV 3 infection/vaccination

prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesis

(2023) Kimberly A. Dowd et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity

(2023) Ellen Young et al.   Nature Communications

Genomewide CRISPR knockout screen identified PLAC8 as an essential factor for SADS-CoVs infection

(2022) Longping V. Tse et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Generation of Mature DENVs via Genetic Modification and Directed Evolution

(2022) Longping V. Tse et al.   mBio

Vaccine-induced antibodies to contemporary strains of dengue virus type 4 show a mechanistic correlate of protective immunity

(2022) Emily N. Gallichotte et al.   Cell Reports

Immune Imprinting Drives Human Norovirus Potential for Global Spread

(2022) Lisa C. Lindesmith et al.   mBio

A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans

(2021) Usha K. Nivarthi et al.   Nature Communications

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)

(2021) Laura J. White et al.   PLoS Neglected Tropical Diseases

A Review on Dengue Vaccine Development

(2020) Sheng-Qun Deng et al.   Vaccines

Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies

(2020) Ellen Young et al.   Cell Host & Microbe

Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial

(2020) Shibadas Biswal et al.   LANCET

Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus

(2020) Gustavo H. Dayan et al.   VACCINE

Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus

(2020) Gustavo H. Dayan et al.   VACCINE

Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees

(2020) David R. Martinez et al.   Cell Reports

Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by NIH Monovalent Dengue Virus Vaccines

(2019) Jesica A Swanstrom et al.   JOURNAL OF INFECTIOUS DISEASES

Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies

(2019) Emily N. Gallichotte et al.   mBio

Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents

(2019) Shibadas Biswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas

(2019) Daniela V. Andrade et al.   Scientific Reports

Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: A phase 2, double-blind, randomised, controlled trial

(2019) Vianney Tricou et al.   VACCINE

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

(2018) Saranya Sridhar et al.   NEW ENGLAND JOURNAL OF MEDICINE

The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection

(2018) Leah C Katzelnick et al.   Current Opinion in Virology

Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes

(2018) Emily N. Gallichotte et al.   PLoS Pathogens

Reconstruction of antibody dynamics and infection histories to evaluate dengue risk

(2018) Henrik Salje et al.   NATURE

Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies

(2018) Rajendra Raut et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization

(2018) Emily N. Gallichotte et al.   Cell Reports

Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America

(2017) Zoe Moodie et al.   JOURNAL OF INFECTIOUS DISEASES

Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine

(2017) Diogo M. Magnani et al.   JOURNAL OF VIROLOGY

Antibody-dependent enhancement of severe dengue disease in humans

(2017) Leah C. Katzelnick et al.   SCIENCE

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?

(2017) Aravinda M. de Silva et al.   Cold Spring Harbor Perspectives in Biology

Dissecting the human serum antibody response to secondary dengue virus infections

(2017) Bhumi Patel et al.   PLoS Neglected Tropical Diseases

Epitope Addition and Ablation via Manipulation of a Dengue Virus Serotype 1 Infectious Clone

(2017) Emily N. Gallichotte et al.   mSphere

Homotypic Dengue Virus Reinfections in Nicaraguan Children

(2016) Jesse J. Waggoner et al.   JOURNAL OF INFECTIOUS DISEASES

Dengue Viruses and Lifelong Immunity: Reevaluating the Conventional Wisdom

(2016) Brett M. Forshey et al.   JOURNAL OF INFECTIOUS DISEASES

Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1

(2016) William B. Messer et al.   JOURNAL OF VIROLOGY

Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort

(2016) Leah C. Katzelnick et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

(2015) Wanwisa Dejnirattisai et al.   NATURE IMMUNOLOGY

Broad and strong: the ultimate antibody to dengue virus

(2015) Josefina Coloma et al.   NATURE IMMUNOLOGY

Climate change influences on global distributions of dengue and chikungunya virus vectors

(2015) L. P. Campbell et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Asymptomatic humans transmit dengue virus to mosquitoes

(2015) Veasna Duong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers

(2015) G. Fibriansah et al.   SCIENCE

Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study

(2015) Richard Rupp et al.   VACCINE

Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host

(2015) Richard J. Kuhn et al.   VIROLOGY

A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies

(2015) E. N. Gallichotte et al.   mBio

A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins

(2015) Guntur Fibriansah et al.   Nature Communications

A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface

(2014) Guntur Fibriansah et al.   EMBO Molecular Medicine

Dengue virus envelope protein domain I/II hinge: a key target for dengue virus vaccine design?

(2014) Douglas G Widman et al.   Expert Review of Vaccines

Isolation of Dengue Virus-Specific Memory B Cells with Live Virus Antigen from Human Subjects following Natural Infection Reveals the Presence of Diverse Novel Functional Groups of Antibody Clones

(2014) S. A. Smith et al.   JOURNAL OF VIROLOGY

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

(2014) Maria Rosario Capeding et al.   LANCET

A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

(2014) Wanwisa Dejnirattisai et al.   NATURE IMMUNOLOGY

Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera

(2014) Ruklanthi de Alwis et al.   PLoS Pathogens

Epidemiological Risk Factors Associated with High Global Frequency of Inapparent Dengue Virus Infections

(2014) Laura Grange et al.   Frontiers in Immunology

The global distribution and burden of dengue

(2013) Samir Bhatt et al.   NATURE

Stability of trimeric DENV envelope protein at low and neutral pH: An insight from MD study

(2012) Kshatresh Dutta Dubey et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Dengue

(2012) Cameron P. Simmons et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

(2012) R. de Alwis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Structural Basis for Serotype-Specific Neutralization of Dengue Virus by a Human Antibody

(2012) E. P. Teoh et al.   Science Translational Medicine

Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus

(2012) Oliver J. Brady et al.   PLoS Neglected Tropical Diseases

Development and Characterization of a Reverse Genetic System for Studying Dengue Virus Serotype 3 Strain Variation and Neutralization

(2012) William B. Messer et al.   PLoS Neglected Tropical Diseases

Efficacy of a Tetravalent Chimeric Dengue Vaccine (DENVax) in Cynomolgus Macaques

(2011) Jorge E. Osorio et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Immune Response to Dengue Virus and Prospects for a Vaccine

(2011) Brian R. Murphy et al.   Annual Review of Immunology

Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

(2011) Jorge E. Osorio et al.   VACCINE

Dengue — Quo tu et quo vadis?

(2011) Rubing Chen et al.   Viruses-Basel

The Human Antibody Response to Dengue Virus Infection

(2011) Wahala M. P. B. Wahala et al.   Viruses-Basel

The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity

(2010) Martina Beltramello et al.   Cell Host & Microbe

Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354

(2010) B. Kaufmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses

(2010) Wahala M. P. B. Wahala et al.   PLoS Pathogens

The Nicaraguan Pediatric Dengue Cohort Study: Study Design, Methods, Use of Information Technology, and Extension to Other Infectious Diseases

(2009) G. Kuan et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Molecular evolution of dengue viruses: Contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease

(2009) Scott C. Weaver et al.   INFECTION GENETICS AND EVOLUTION

Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection

(2008) Theodore C. Pierson et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE